NF2 and neoplasm: To characterize the effects of recurrent mutations in Hippo pathway core components in human tumor cells, we measured TEAD transcriptional activity in several tumor lines bearing loss of function mutations in NF2 (H2373, MESO25) [11], LATS1 (MSTO-211H (211H)) [23] and NF2/LATS2 (H2052) [11] or in immortalized non-tumorigenic (293T, MCF10A) cell lines, which are wild-type for NF2, LATS1 and LATS2 genes (Supplementary Figure S1A).